Shimamoto K, Ura N, Tanaka S, Ogasawara A, Nakao T, Nakahashi Y, Chao J, Margolius H S, Iimura O
Jpn Circ J. 1981 Sep;45(9):1092-7. doi: 10.1253/jcj.45.1092.
Recently, we established a very sensitive, specific and simple direct radioimmunoassay method for human urinary kallikrein. In this study, in order to clarify whether or not the low or high excretion rate of urinary kallikrein activity in patients with essential hypertension, primary aldosteronism, pheochromocytoma and Bartter's syndrome is caused by changes in enzyme quantity, urinary kallikrein excretion was measured with this direct radioimmunoassay method in normal subjects and in patients with these diseases. Urinary kallikrein excretion measured as enzyme quantity was significantly lower in patients with essential hypertension, and higher in patients with primary aldosteronism and Bartter's syndrome. These results are consistent with other previously reported data and our data measured by means of esterase assay or kininogenase assay. The results also suggest that lowered or elevated excretion of urinary kallikrein activity in these diseases is caused, in part at least, by the lowered or elevated excretion of enzyme quantity.
最近，我们建立了一种用于检测人尿激肽释放酶的非常灵敏、特异且简便的直接放射免疫分析方法。在本研究中，为了阐明原发性高血压、原发性醛固酮增多症、嗜铬细胞瘤和巴特综合征患者尿激肽释放酶活性的排泄率低或高是否由酶量的变化引起，我们用这种直接放射免疫分析方法对正常受试者和患有这些疾病的患者的尿激肽释放酶排泄情况进行了检测。以酶量衡量的尿激肽释放酶排泄量在原发性高血压患者中显著降低，而在原发性醛固酮增多症和巴特综合征患者中则升高。这些结果与之前其他报道的数据以及我们通过酯酶测定或激肽原酶测定所得到的数据一致。这些结果还表明，在这些疾病中尿激肽释放酶活性排泄的降低或升高至少部分是由酶量排泄的降低或升高所导致的。
